We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+18.13%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$767M
AUM Growth
+$137M
Cap. Flow
+$31.2M
Cap. Flow %
4.08%
Top 10 Hldgs %
34.48%
Holding
123
New
27
Increased
33
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$14.4M
2
CYTK icon
Cytokinetics
CYTK
+$12.9M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$10.3M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$7.27M

Top Sells

Rank Stock Value
1
NVMI
Nova
NVMI
+$14.5M
2
TSEM icon
Tower Semiconductor
TSEM
+$8.98M
3
FOLD
Amicus Therapeutics
FOLD
+$8.72M
4
CLBT icon
Cellebrite
CLBT
+$8.7M
5
APLS
Apellis Pharmaceuticals
APLS
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 80.09%
2 Miscellaneous 10.43%
3 Technology 7.55%
4 Utilities 1.93%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PALI icon
51
Palisade Bio
PALI
$356M
$4.72M 0.62%
2,257,106
+523,635
+30% +$1.03M
ELDN icon
52
Eledon Pharmaceuticals
ELDN
$238M
$4.69M 0.61%
1,191,187
-580,944
-33% -$2.11M
VST icon
53
Vistra
VST
$48.4B
$4.67M 0.61%
+29,450
New +$4.57M
TLN
54
Talen Energy Corp
TLN
$14.6B
$4.66M 0.61%
+12,135
New +$4.45M
SVRA icon
55
Savara
SVRA
$1.1B
$4.66M 0.61%
756,164
+17,000
+2% +$91.2K
IRON icon
56
Disc Medicine
IRON
$3.05B
$4.65M 0.61%
63,538
+10,000
+19% +$687K
CLOU icon
57
Global X Cloud Computing ETF
CLOU
$378M
$4.45M 0.58%
+195,900
New +$4.24M
DYN icon
58
Dyne Therapeutics
DYN
$4.66B
$4.43M 0.58%
199,594
+39,000
+24% +$725K
RLAY icon
59
Relay Therapeutics
RLAY
$4.17B
$4.38M 0.57%
233,836
-174,600
-43% -$2.53M
AVTX icon
60
Avalo Therapeutics
AVTX
$1.02B
$4.29M 0.56%
+232,294
New +$3.67M
PMN icon
61
ProMIS Neurosciences
PMN
$116M
$4.28M 0.56%
325,591
– –
BCRX icon
62
BioCryst Pharmaceuticals
BCRX
$2.58B
$4.22M 0.55%
422,051
-444,413
-51% -$4.02M
RVMD icon
63
Revolution Medicines
RVMD
$45.2B
$4.2M 0.55%
22,400
-32,710
-59% -$4.78M
PRAX icon
64
CALL
Praxis Precision Medicines
PRAX
$9.92B
$4.18M 0.55%
+12,500
New +$3.96M
CABA icon
65
Cabaletta Bio
CABA
$590M
$4.13M 0.54%
+1,329,012
New +$4.37M
GENB
66
Generate Biomedicines
GENB
$2.1B
$4.13M 0.54%
245,000
+60,000
+32% +$817K
TLT icon
67
CALL
iShares 20+ Year Treasury Bond ETF
TLT
$46.5B
$4.06M 0.53%
47,000
– –
MDWD icon
68
MediWound
MDWD
$171M
$4.02M 0.52%
273,192
– –
ACOG
69
Alpha Cognition
ACOG
$201M
$3.94M 0.51%
545,816
-21,800
-4% -$136K
WVE icon
70
Wave Life Sciences
WVE
$926M
$3.71M 0.48%
638,272
+90,000
+16% +$597K
CRVS icon
71
Corvus Pharmaceuticals
CRVS
$1.23B
$3.66M 0.48%
244,961
-3,000
-1% -$41.6K
OVID icon
72
Ovid Therapeutics
OVID
$543M
$3.64M 0.47%
1,353,000
-269,828
-17% -$696K
BBOT
73
BridgeBio Oncology
BBOT
$714M
$3.51M 0.46%
+460,985
New +$3.85M
CTMX icon
74
CytomX Therapeutics
CTMX
$802M
$3.3M 0.43%
879,000
+659,000
+300% +$2.52M
PRQR icon
75
ProQR Therapeutics
PRQR
$295M
$3.27M 0.43%
+1,757,458
New +$2.89M
1 2
3
4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2026 Portfolio in Review

As of Q2 2026, Sphera Funds Management held 123 positions worth $767M, up 22% from $630M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Sphera Funds Management deployed $31.2M of net new capital in Q2 2026, opening 27 new positions and adding to 33 existing holdings. Its largest new stake was Insmed: 118,800 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 74% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Nova, an estimated $14.5M trimmed.

  • Sphera Funds Management's largest Q2 2026 buy was Insmed: 118,800 shares worth $12.7M.
  • Sphera Funds Management added most to Cytokinetics in Q2 2026, an estimated $12.9M increase.
  • Sphera Funds Management's biggest Q2 2026 reduction was Nova, cutting an estimated $14.5M.
  • Sphera Funds Management fully exited Amicus Therapeutics in Q2 2026, selling an estimated $8.72M.
  • Sphera Funds Management's ten largest holdings make up 34% of its $767M portfolio in Q2 2026.
  • Sphera Funds Management opened 27 new positions and closed 18 in Q2 2026.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $767M.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.